These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Recent advances in the understanding and care of familial hypercholesterolaemia: significance of the biology and therapeutic regulation of proprotein convertase subtilisin/kexin type 9. Page MM; Stefanutti C; Sniderman A; Watts GF Clin Sci (Lond); 2015 Jul; 129(1):63-79. PubMed ID: 25881720 [TBL] [Abstract][Full Text] [Related]
4. PCSK9 R46L, lower LDL, and cardiovascular disease risk in familial hypercholesterolemia: a cross-sectional cohort study. Saavedra YG; Dufour R; Davignon J; Baass A Arterioscler Thromb Vasc Biol; 2014 Dec; 34(12):2700-5. PubMed ID: 25278291 [TBL] [Abstract][Full Text] [Related]
5. Improving the detection of familial hypercholesterolaemia. Lan NSR; Martin AC; Brett T; Watts GF; Bell DA Pathology; 2019 Feb; 51(2):213-221. PubMed ID: 30579649 [TBL] [Abstract][Full Text] [Related]
6. The management of familial hypercholesterolaemia in Morocco. El Messal M; Aït Chihab K; Chater R; Loutfi M; Kettani A; Hafidi A; Adlouni A Acta Cardiol; 2006 Oct; 61(5):551-5. PubMed ID: 17117756 [TBL] [Abstract][Full Text] [Related]
7. Leucine 10 allelic variant in signal peptide of PCSK9 increases the LDL cholesterol-lowering effect of statins in patients with familial hypercholesterolaemia. Pisciotta L; Sallo R; Rabacchi C; Wunsch A; Calandra S; Bertolini S Nutr Metab Cardiovasc Dis; 2012 Oct; 22(10):831-5. PubMed ID: 21920719 [TBL] [Abstract][Full Text] [Related]
9. Causative mutations and premature cardiovascular disease in patients with heterozygous familial hypercholesterolaemia. Rubba P; Gentile M; Marotta G; Iannuzzi A; Sodano M; De Simone B; Jossa F; Iannuzzo G; Giacobbe C; Di Taranto MD; Fortunato G Eur J Prev Cardiol; 2017 Jul; 24(10):1051-1059. PubMed ID: 28353356 [TBL] [Abstract][Full Text] [Related]
10. Next-generation-sequencing-based identification of familial hypercholesterolemia-related mutations in subjects with increased LDL-C levels in a latvian population. Radovica-Spalvina I; Latkovskis G; Silamikelis I; Fridmanis D; Elbere I; Ventins K; Ozola G; Erglis A; Klovins J BMC Med Genet; 2015 Sep; 16():86. PubMed ID: 26415676 [TBL] [Abstract][Full Text] [Related]
11. Genetic analysis of familial hypercholesterolaemia in Western Australia. Hooper AJ; Nguyen LT; Burnett JR; Bates TR; Bell DA; Redgrave TG; Watts GF; van Bockxmeer FM Atherosclerosis; 2012 Oct; 224(2):430-4. PubMed ID: 22883975 [TBL] [Abstract][Full Text] [Related]
12. Therapeutic Management of Familial Hypercholesterolemia: Current and Emerging Drug Therapies. Patel RS; Scopelliti EM; Savelloni J Pharmacotherapy; 2015 Dec; 35(12):1189-203. PubMed ID: 26684558 [TBL] [Abstract][Full Text] [Related]
13. Familial Hypercholesterolaemia in the Era of Genetic Testing. Hughes DP; Viljoen A; Wierzbicki AS Curr Cardiol Rep; 2016 May; 18(5):42. PubMed ID: 27002618 [TBL] [Abstract][Full Text] [Related]
14. Serum levels of proprotein convertase subtilisin/kexin type 9 in subjects with familial hypercholesterolemia indicate that proprotein convertase subtilisin/kexin type 9 is cleared from plasma by low-density lipoprotein receptor-independent pathways. Cameron J; Bogsrud MP; Tveten K; Strøm TB; Holven K; Berge KE; Leren TP Transl Res; 2012 Aug; 160(2):125-30. PubMed ID: 22683370 [TBL] [Abstract][Full Text] [Related]
15. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial. Raal F; Scott R; Somaratne R; Bridges I; Li G; Wasserman SM; Stein EA Circulation; 2012 Nov; 126(20):2408-17. PubMed ID: 23129602 [TBL] [Abstract][Full Text] [Related]
16. Next generation sequencing to identify novel genetic variants causative of autosomal dominant familial hypercholesterolemia associated with increased risk of coronary heart disease. Al-Allaf FA; Athar M; Abduljaleel Z; Taher MM; Khan W; Ba-Hammam FA; Abalkhail H; Alashwal A Gene; 2015 Jul; 565(1):76-84. PubMed ID: 25839937 [TBL] [Abstract][Full Text] [Related]
17. Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial. Raal FJ; Honarpour N; Blom DJ; Hovingh GK; Xu F; Scott R; Wasserman SM; Stein EA; Lancet; 2015 Jan; 385(9965):341-50. PubMed ID: 25282520 [TBL] [Abstract][Full Text] [Related]
18. Genetics of familial hypercholesterolemia. Brautbar A; Leary E; Rasmussen K; Wilson DP; Steiner RD; Virani S Curr Atheroscler Rep; 2015 Apr; 17(4):491. PubMed ID: 25712136 [TBL] [Abstract][Full Text] [Related]
19. Screening and treatment of familial hypercholesterolemia - Lessons from the past and opportunities for the future (based on the Anitschkow Lecture 2014). Besseling J; Sjouke B; Kastelein JJ Atherosclerosis; 2015 Aug; 241(2):597-606. PubMed ID: 26115072 [TBL] [Abstract][Full Text] [Related]
20. The molecular genetic basis and diagnosis of familial hypercholesterolemia in Denmark. Jensen HK Dan Med Bull; 2002 Nov; 49(4):318-45. PubMed ID: 12553167 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]